SELEXIPAG

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H32N4O4S
Molecular Weight	496.622
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SELEXIPAG

Structure Search

SMILES

CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3

InChI

InChIKey=QXWZQTURMXZVHJ-UHFFFAOYSA-N

InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)

HIDE SMILES / InChI

Molecular Formula	C26H32N4O4S
Molecular Weight	496.622
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:26:53 UTC 2023` Edited by `admin` on `Sat Dec 16 17:26:53 UTC 2023`
Record UNII	5EXC0E384L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SELEXIPAG

Official Name

English

SELEXIPAG [USAN]

Common Name

English

Selexipag [WHO-DD]

Common Name

English

selexipag [INN]

Common Name

English

2-{4-[(5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide

Systematic Name

English

SELEXIPAG [JAN]

Common Name

English

SELEXIPAG [ORANGE BOOK]

Common Name

English

UPTRAVI

Brand Name

English

ACT-293987

Code

English

SELEXIPAG [MI]

Common Name

English

NS-304

Code

English

Classification Tree Code System Code

NDF-RT

N0000192339

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

FDA ORPHAN DRUG

652018

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

WHO-ATC

B01AC27

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

NCI_THESAURUS

C78568

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

EMA ASSESSMENT REPORTS

UPTRAVI (AUTHORIZED: HYPERTENSION, PULMONARY)

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

FDA ORPHAN DRUG

304810

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

Code System Code Type Description

RXCUI

1729002

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

ChEMBL

CHEMBL238804

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

WIKIPEDIA

Selexipag

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

PUBCHEM

9913767

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

FDA UNII

5EXC0E384L

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

MERCK INDEX

m11914

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

NCI_THESAURUS

C152321

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

DRUG BANK

DB11362

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

SMS_ID

100000156702

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

CHEBI

90844

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

DRUG CENTRAL

5077

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

CAS

475086-01-2

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

INN

9231

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

EPA CompTox

DTXSID301027959

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

USAN

YY-107

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

EVMPD

SUB130805

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

EU-Orphan Drug

EU/3/05/316(WITHDRAWN)

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2016 on request of the Sponsor, at the time of the granting of a marketing authorisation. On 26 August 2005, orphan designation (EU/3/05/316) was granted by the European Commission to Nippon Shinyaku Co. Ltd, Germany, for 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide for the treatment of pulmonary arterial hypertension and chronic thromoembolic pulmonary hypertension. The sponsorship was transferred to Actelion Registration Limited, United Kingdom, in February 2009. Update: 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide has been authorised in the EU as Uptravi since 12 May 2016. More information on Uptravi can be found in the European public assessment report (EPAR) on the Agency’s website.

NDF-RT

N0000020068

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

Prostacyclin Receptor Agonists [MoA]

DAILYMED

5EXC0E384L

Created by admin on Sat Dec 16 17:26:55 UTC 2023 , Edited by admin on Sat Dec 16 17:26:55 UTC 2023

PRIMARY

Related Record Type Details


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> SUBSTRATE


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> INHIBITOR

Qualification:

IC50

Amount:


					AIN96D6SGL

OATP1B1

TRANSPORTER -> SUBSTRATE


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					66DDF797LP

OATP-8

TRANSPORTER -> SUBSTRATE


					AIN96D6SGL

OATP1B1

TRANSPORTER -> INHIBITOR

Qualification:

IC50

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					66DDF797LP

OATP-8

TRANSPORTER -> INHIBITOR

Qualification:

IC50

Amount:


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> INHIBITOR

Qualification:

IC50

Amount:


					5EXC0E384L

SELEXIPAG

EXCRETED UNCHANGED

Comments:

No unchanged selexipag is excreted in the urine and feces.

Qualification:

FECAL; URINE

Amount:


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR

Qualification:

IC50

Amount:


					HPN66MJEK8

LIVER CARBOXYLESTERASE 1

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR

Amount:


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> INHIBITOR

Qualification:

IC50

Amount:


					66UL4XJJ3X

PROSTACYCLIN RECEPTOR

TARGET -> AGONIST

Qualification:

EC50

Amount:

Related Record Type Details


					E9PC7N0DID

METABOLITE ACTIVE -> PARENT


					ME9QGL9THJ

(2S,3S,4S,5R,6S)-6-(2-(4-((5,6-DIPHENYLPYRAZIN-2-YL)-ISOPROPYL-AMINO)BUTOXY)ACETYL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Related Record Type Details


					5EXC0E384L

SELEXIPAG

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION